Circulating tumor cells (CTCs) have significant potential to become an important tool for monitoring the effects of treatment in solid tumors. The present study reports the occurance of CTCs in cervical cancer (CC) patients during radical chemoradiotherapy (CRT), including brachytherapy (BRT), and during the follow-up period. Patients diagnosed with CC treated with radical CRT were included in the study (n=30). A total of 167 CTC-tests (MetaCell®) were provided at predefined testing time points during the study follow-up (e.g., before CRT, after CRT, every three months of follow-up). In parallel with CTC-testing, SCC-Ag were measured to compare their predictive values during treatment. CTCs were present in 96% (25/26) of patients at the time of diagnosis and in 61% (14/23) after treatment. Patients who relapsed during the 36-month follow-up (n=10) showed an elevation in pre-treatment CTC- numbers, similarly there was a significant increase in pre-treatment SCC-Ag. As next, an increased number of CTCs was observed approximately 12 weeks before relapse was diagnosed by standard imaging modalities (MRI, US, PET-CT) in 3 of 4 patients. In addition to standardized vital cytomorphology of enriched CTCs, quantitative PCR (qPCR) was used to inform the nature of CTCs before treatment. Analysis revealed increased SOX2 and POUSF expression in CTCs in the group of patients with recurrence (P < 0.02). Disease aggressiveness may be related to increased expression of stem cell markers, as found in samples from relapsed patients. CTCs may be an aid to assess tumor burden and disease aggressiveness. An increase in CTCs precedes an increase in SCC-Ag and confirmation of relapse by imaging, as shown in our study.

3rd Department of Surgery 1st Faculty of Medicine Charles University 5 Uvalu 84 150 06 Prague 5 Czech Republic

Department of Gynaecology Military University Hospital and The 3rd Faculty of Medicine U Vojenske Nemocnice 1200 169 02 Prague 6 Czech Republic

Department of Oncology The 3rd Faculty of Medicine Charles University Prague and Faculty Hospital Kralovske Vinohrady Srobarova 50 100 34 Prague 10 Czech Republic

Department of Thoracic Surgery Krajská zdravotní a s Hospital 41100 Ústí nad Labem Czech Republic

Department of Thoracic Surgery Lower Silesian Oncology Pulmonology and Hematology Center and Technical University Wroclaw Plac Ludwika Hirszfelda 12 534 13 Wrocław Poland

Laboratory of Personalized Medicine Oncology Clinic Faculty Hospital Kralovske Vinohrady Srobarova 50 100 34 Prague 10 Czech Republic

Zobrazit více v PubMed

Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: a global health crisis. Cancer. 2017;123:2404–2412. PubMed

Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393:169–182. PubMed

Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191–e203. PubMed PMC

Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol. 2008;110(Suppl 2):S4–S7. PubMed

Cascardi E, Cazzato G, Daniele A, Silvestris E, Cormio G, Di Vagno G, Malvasi A, Loizzi V, Scacco S, Pinto V, Cicinelli E, Maiorano E, Ingravallo G, Resta L, Minoia C, Dellino M. Association between cervical microbiota and HPV: could this be the key to complete cervical cancer eradication? Biology (Basel) 2022;11:1114. PubMed PMC

Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N ESMO Guidelines Committee. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv262. PubMed

Waggoner SE. Cervical cancer. Lancet. 2003;361:2217–2225. PubMed

Bonfrer JMG, Duffy MJ, Radtke M, Segurado O, Torre GC, Van Dalen A, Zwirner M. Tumour markers in gynaecological cancers--EGTM recommendations. European Group on Tumor Markers. Anticancer Res. 1999;19:2807–2810. PubMed

Duk JM, de Bruijn HW, Groenier KH, Hollema H, ten Hoor KA, Krans M, Aalders JG. Cancer of the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen determinations. Gynecol Oncol. 1990;39:186–194. PubMed

Jeong BK, Choi DH, Huh SJ, Park W, Bae DS, Kim BG. The role of squamous cell carcinoma antigen as a prognostic and predictive factor in carcinoma of uterine cervix. Radiat Oncol J. 2011;29:191–198. PubMed PMC

Wülfing P, Borchard J, Buerger H, Heidl S, Zänker KS, Kiesel L, Brandt B. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res. 2006;12:1715–1720. PubMed

Romero-Laorden N, Olmos D, Fehm T, Garcia-Donas J, Diaz-Padilla I. Circulating and disseminated tumor cells in ovarian cancer: a systematic review. Gynecol Oncol. 2014;133:632–639. PubMed

Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008;26:3213–3221. PubMed

Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J, Xu Y. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol. 2011;137:1151–1173. PubMed

Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2015;7:1–11. PubMed PMC

Liu MC, Janni W, Georgoulias V, Yardley DA, Harbeck N, Wei X, McGovern D, Beck R. First-line doublet chemotherapy for metastatic triple-negative breast cancer: circulating tumor cell analysis of the tnAcity trial. Cancer Manag Res. 2019;11:10427–10433. PubMed PMC

Wallwiener M, Riethdorf S, Hartkopf AD, Modugno C, Nees J, Madhavan D, Sprick MR, Schott S, Domschke C, Baccelli I, Schönfisch B, Burwinkel B, Marmé F, Heil J, Sohn C, Pantel K, Trumpp A, Schneeweiss A. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. BMC Cancer. 2014;14:512. PubMed PMC

Larsson AM, Jansson S, Bendahl PO, Levin Tykjaer Jörgensen C, Loman N, Graffman C, Lundgren L, Aaltonen K, Rydén L. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res. 2018;20:48. PubMed PMC

Ring A, Nguyen-Sträuli BD, Wicki A, Aceto N. Biology, vulnerabilities and clinical applications of circulating tumour cells. Nat Rev Cancer. 2023;23:95–111. PubMed PMC

Okazawa-Sakai M, Mabuchi S, Isohashi F, Kawashima A, Yokoi E, Ogawa K, Kimura T. Predictors of distant relapse in patients with FIGO stage IIB-IVA cervical cancer treated with definitive radiotherapy. J Obstet Gynaecol Res. 2017;43:1743–1750. PubMed

Wen YF, Cheng TT, Chen XL, Huang WJ, Peng HH, Zhou TC, Lin XD, Zeng LS. Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy. PLoS One. 2018;13:e0204334. PubMed PMC

Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, Köhler C, Landoni F, Lax S, Lindegaard JC, Mahantshetty U, Mathevet P, McCluggage WG, McCormack M, Naik R, Nout R, Pignata S, Ponce J, Querleu D, Raspagliesi F, Rodolakis A, Tamussino K, Wimberger P, Raspollini MR. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiother Oncol. 2018;127:404–416. PubMed

Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, Matulonis UA. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol. 2013;131:352–356. PubMed

Jacob K, Sollier C, Jabado N. Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteomics. 2007;4:741–756. PubMed

Rodriguez-Tirado C, Kale N, Carlini MJ, Shrivastava N, Rodrigues AA, Khalil BD, Bravo-Cordero JJ, Hong Y, Alexander M, Ji J, Behbod F, Sosa MS. NR2F1 is a barrier to dissemination of early-stage breast cancer cells. Cancer Res. 2022;82:2313–2326. PubMed PMC

Klezl P, Pospisilova E, Kolostova K, Sonsky J, Maly O, Grill R, Pawlak I, Bobek V. Detection of circulating tumor cells in renal cell carcinoma: disease stage correlation and molecular characterization. J Clin Med. 2020;9:1372. PubMed PMC

Kolostova K, Spicka J, Matkowski R, Bobek V. Isolation, primary culture, morphological and molecular characterization of circulating tumor cells in gynecological cancers. Am J Transl Res. 2015;7:1203–1213. PubMed PMC

Markovina S, Wang S, Henke LE, Luke CJ, Pak SC, Dewees T, Pfeifer JD, Schwarz JK, Liu W, Chen S, Mutch D, Wang X, Powell MA, Siegel BA, Dehdashti F, Silverman GA, Grigsby PW. Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. Br J Cancer. 2018;118:72–78. PubMed PMC

Wang S, Luke CJ, Pak SC, Shi V, Chen L, Moore J, Andress AP, Jayachandran K, Zhang J, Huang Y, Platik M, Apicelli AA, Schwarz JK, Grigsby PW, Silverman GA, Markovina S. SERPINB3 (SCCA1) inhibits cathepsin L and lysoptosis, protecting cervical cancer cells from chemoradiation. Commun Biol. 2022;5:46. PubMed PMC

Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ. Circulating tumor cells in advanced cervical cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062) Mol Cancer Ther. 2020;19:2363–2370. PubMed PMC

Cafforio P, Palmirotta R, Lovero D, Cicinelli E, Cormio G, Silvestris E, Porta C, D’Oronzo S. Liquid biopsy in cervical cancer: hopes and pitfalls. Cancers (Basel) 2021;13:3968. PubMed PMC

Du K, Huang Q, Bu J, Zhou J, Huang Z, Li J. Circulating tumor cells counting act as a potential prognostic factor in cervical cancer. Technol Cancer Res Treat. 2020;19:1533033820957005. PubMed PMC

Nesbit EA, Driskill E, Robinson P, Murphy K, Andrade J, Showalter TN, Janowski EM, Romano K. The role of circulating tumor cells as potential predictive and prognostic factors in cervical cancers. Int J Radiat Oncol Bio Phys. 2022;114:91.

Lawrence R, Watters M, Davies CR, Pantel K, Lu YJ. Circulating tumour cells for early detection of clinically relevant cancer. Nat Rev Clin Oncol. 2023;20:487–500. PubMed PMC